Cargando…
Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma
ARID1A is among the most commonly mutated tumor suppressor genes in hepatocellular carcinoma (HCC). In this study, we conduct a CRISPR-Cas9 synthetic lethality screen using ARID1A-deficient HCC cells to identify approaches to treat HCC patients harboring ARID1A deficiency. This strategy reveals that...
Autores principales: | Xing, Tao, Li, Li, Chen, Yiran, Ju, Gaoda, Li, Guilan, Zhu, Xiaoyun, Ren, Yubo, Zhao, Jing, Cheng, Zhilei, Li, Yan, Xu, Da, Liang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694624/ https://www.ncbi.nlm.nih.gov/pubmed/37939712 http://dx.doi.org/10.1016/j.xcrm.2023.101264 |
Ejemplares similares
-
A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma
por: Zhang, Qi, et al.
Publicado: (2022) -
Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway
por: Li, Su-Ran, et al.
Publicado: (2022) -
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016) -
Human Umbilical
Vein Endothelial Cells Survive on
the Ischemic TCA Cycle under Lethal Ischemic Conditions
por: Mao, Lisha, et al.
Publicado: (2022) -
TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
por: Todisco, Simona, et al.
Publicado: (2019)